Alkermes plc (NASDAQ:ALKS) is one of the stocks Jim Cramer recently looked at. When a caller asked Cramer about the stock, he ...

Earlier this month, Alkermes plc announced that the FDA granted Breakthrough Therapy designation to alixorexton, its oral ...

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1, based ...

The latest announcement is out from Alkermes ( ($ALKS) ). On January 6, 2026, Alkermes announced that the U.S. Food and Drug Administration ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ...

As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR ...

Jackson stated, "As we look ahead, based on our performance during the first half of the year and the expected contribution from our expanded sales efforts, we are on track to deliver record revenues ...

Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2). Narcolepsy type ...

DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday, Sept.